prostacyclin

(redirected from Flolan)
Also found in: Medical.

pros·ta·cy·clin

 (prŏs′tə-sī′klĭn)
n.
A prostaglandin produced in the walls of blood vessels that acts as a vasodilator and inhibits platelet aggregation.

prostacyclin

(ˌprɒstəˈsaɪklɪn)
n
(Biochemistry) biochem any of several prostaglandins produced in the blood vessels, causing vasodilation and inhibiting platelet aggregation

pros•ta•cy•clin

(ˌprɒs təˈsaɪ klɪn)

n.
a prostaglandin, C20H32O5, that specifically inhibits the formation of blood clots.
[1975–80; prosta (te) + cycl (ic) + -in1, on the model of prostaglandin]
References in periodicals archive ?
The catheter had been placed approximately 3 years earlier for administration of continuous Flolan therapy to control pulmonary hypertension.
8% Adcirca, Letaris, Retavio, Hypertension (PAH) Tracleer, Tyvaso, Venvatis, Flolan, Remodulin Growth Hormone 3.
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).
Actelion said it will also provide further information on VELETRI at the American Heart Association Scientific Sessions 2010 in Chicago with a poster entitled "Biocomparability of Two Formulations of Epoprostenol, Epoprostenol for Injection (ACT-385781A) And Flolan, Via Pharmacokinetic Assessment of Two Primary Metabolites.
Drug administration and dosages may include Flolan or epoprostenol, via continuous IV infusion via central venous catheter using an ambulatory infusion pump 1 to 20 ng/kg/min, treprostinil (Remodulin), continuous subcutaneous infusion 0.
A randomized controlled trial of epoprostenol therapy for severe congestive heartfailure:The Flolan International Randomized Survival Trial (FIRST).
Across the Atlantic, the US Food & Drug Administration approved Teva Pharmaceutical's application to market its rival generic version of GlaxoSmithKline's drug Flolan.
Other services provided by Accredo for patients receiving Flolan includes benefit coordination, patient education, prescriber support, and product dispensing and compliance management.
Tracleer, which was the second-to-launch agent for PAH in the United States (2001) after epoprostenol (GlaxoSmithKline/Gilead's Flolan, Actelion's Veletri, generics), has been used in the treatment of PAH for almost a decade and is regarded by many physicians as offering the best balance between documented efficacy, safety and tolerability, and delivery in the majority of PAH patients.
The Flolan International Randomized Survival Trial (FIRST) of intravenous epoprostenol for heart failure showed no improvement in distance walked, quality of life, or morbid events and a trend to an increased mortality in patients receiving the study drug (12).
The Phase IV study involves a randomized transition of patients treated with Flolan, a synthetic form of prostacyclin that is delivered intravenously, to either subcutaneous Remodulin or to placebo.
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).